Hu23F2G humanized antibody: Delayed the start of a Phase I study,

Icos Corp. (ICOS), Seattle Product: Hu23F2G humanized antibody Indication: Multiple sclerosis Status: The company, which delayed the planned first quarter start of a Phase I study, said it is still di...